Dow Up0.08% Nasdaq Down0.30%

Actavis plc (ACT)

-NYSE
241.81 Up 3.88(1.63%) Sep 19, 4:07PM EDT
|After Hours : 241.79 Down 0.02 (0.01%) Sep 19, 5:00PM EDT
ProfileGet Profile for:
Actavis plc
Morris Corporate Center III
400 Interpace Parkway
Parsippany, NJ 07054
United States - Map
Phone: 862-261-7000
Website: http://www.actavis.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drugs - Generic
Full Time Employees:19,200

Business Summary 

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians’ offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines; and a collaboration agreement with Hanmi Pharm. Co. Ltd. to develop Hyalrheuma, a hyaluronic acid injection for arthritis pain treatment. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Actavis plc

Corporate Governance 
Actavis plc’s ISS Governance QuickScore as of Sep 1, 2014 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 4; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Paul M. Bisaro , 53
Exec. Chairman
5.37M55.23M
Mr. Robert Todd Joyce , 56
Chief Financial Officer of Global
1.25M0.00
Mr. Robert A. Stewart , 46
Chief Operating Officer
N/AN/A
Mr. Brenton L. Saunders J.D., 44
Chief Exec. Officer, Pres and Director
N/AN/A
Mr. James C. D'Arecca , 43
Chief Accounting Officer and VP
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders